Mengwei Zang, M.D., Ph.D.
Associate Professor of Medicine
Direct Contact: email@example.com
The major goal of Zang’s laboratory is to explore new nutrient sensing pathways that regulate hepatic lipidmetabolism and to provide the molecular basis for the identification of the therapeutic potential for metabolic diseases such as type 1 and type 2 diabetes, non-alcoholic fatty liver disease, and alcoholic fatty liver disease, as well as their related cardiovascular complications. Our remarkable findings published in top-ranked journals such as Cell Metabolism have made major contributions to the worldwide interest in SIRT1 and AMPK as potential druggable targets in fatty liver, insulin resistance, and atherosclerosis in type 2 diabetes. The ultimate goal is to generate novel and significant information toward the development of therapeutic strategies to combat diabetes, fatty liver disease, and atherosclerosis.